CXCL13 and hypoparathyroidism-retardation-dysmorphism syndrome: Finally, combination therapies targeting both CXCL13+ CD8+ T cells and CAFs/Treg cells could also be considered to overcome the clinical challenges of acquired resistance in the HRD population and the limited efficacy of PARPi and anti‐PDCD1 combination therapy.